UK scientists excited by surprise £2-billion government windfall


Lilly trial tracked more than 2,100 people diagnosed with mild dementia due to Alzheimer's disease for 18 months. Half received monthly infusions of solanezumab, the other half a placebo. Analysis of people with comparable symptoms in earlier studies of solanezumab had seemed encouraging, but the latest trial indicated only a small cognitive benefit, not… (More)
DOI: 10.1038/nature.2016.21038


  • Blog articles referencing this paper

  • Presentations referencing similar topics